Noble Capital analyst Robert LeBoyer reiterated an Outperform rating and $6.00 price target on Unicycive Therapeutics (NASDAQ: UNCY).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Form 8-K Unicycive Therapeutics, For: May 13May 13, 2024 4:28 PM Unicycive Therapeutics, Inc. (UNCY) Misses Q1 EPS by 82cMay 13, 2024 4:26 PM Unicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 4:16 PM Form 10-Q Unicycive Therapeutics, For: Mar 31May 13, 2024 4:07 PM